ストックスクリーナーアプリを入手
1.14
3.39%
-0.04
前日終値:
$1.18
開ける：
$1.17
24時間の取引高:
134.37K
Relative Volume:
0.51
時価総額：
$21.93M
収益：
-
当期純損益:
$-52.53M
株価収益率:
-0.3115
EPS:
-3.66
ネットキャッシュフロー:
$-39.93M
1週間 パフォーマンス:
-37.53%
1か月 パフォーマンス:
-30.28%
6か月 パフォーマンス:
-21.38%
1年 パフォーマンス:
-30.49%
1日の値動き範囲:
$1.09
$1.21
1週間の範囲:
$1.09
$1.39
52週間の値動き範囲:
$0.9397
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
名前
Unity Biotechnology Inc
セクター
電話
(650) 416-1192
住所
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
UBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
1.14 | 21.93M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
| 2023-11-16 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-01-04 | アップグレード | ROTH Capital | Neutral → Buy |
| 2021-11-10 | アップグレード | Mizuho | Neutral → Buy |
| 2021-06-28 | アップグレード | Citigroup | Sell → Buy |
| 2021-06-07 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-16 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-08-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-08-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-28 | 開始されました | ROTH Capital | Buy |
| 2019-12-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 開始されました | Mizuho | Buy |
| 2018-05-29 | 開始されました | Citigroup | Buy |
| 2018-05-29 | 開始されました | Goldman | Neutral |
| 2018-05-29 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Unity Biotechnology Inc (UBX) 最新ニュース
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo Finance
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga
Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - Marketscreener.com
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire
New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - StockTitan
China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail
UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq
UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire
Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - StockTitan
Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail
3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail
This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail
Unity Biotechnology Reports 2024 Financial Results and Updates - MSN
Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times
Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World
HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World
Analysts Issue Forecasts for UBX Q1 Earnings - Defense World
Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World
UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com
Unity Biotechnology Appoints Dr. Yehia Hashad to Board - TipRanks
UNITY Biotechnology Appoints Industry Leader and - GlobeNewswire
UNITY Biotech Strengthens Board with CMO Appointment Before Key Trial Results - StockTitan
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment - TipRanks
Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year - TipRanks
UNITY Biotechnology Reports Q4 and Full Year 2024 Financial Results and Anticipates ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-K Report - TradingView
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewswire
Canadian Investment Regulatory Organization Trading HaltRCK - The Globe and Mail
Korro Bio CFO takes medical leave, interim officers appointed - Investing.com
Annovis Bio (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference - The Globe and Mail
Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431 - MSN
Could 2025 Be a Repeat of 2022 for Big Tech? - The Globe and Mail
Unity Biotechnology CFO sells shares worth $341 By Investing.com - Investing.com Nigeria
Unity Biotechnology Inc (UBX) 財務データ
収益
当期純利益
現金流量
EPS
Unity Biotechnology Inc (UBX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nguyen Alexander Hieu | CLO and Head of Ops |
Feb 04 '25 |
Sale |
2.23 |
164 |
366 |
24,559 |
| Ghosh Anirvan | Chief Executive Officer |
Feb 04 '25 |
Sale |
2.23 |
642 |
1,432 |
75,251 |
| Ghosh Anirvan | Chief Executive Officer |
Nov 04 '24 |
Sale |
1.29 |
432 |
557 |
75,893 |
| Sullivan Lynne Marie | CFO & Head of Corp. Dev. |
Nov 04 '24 |
Sale |
1.29 |
136 |
175 |
55,925 |
| Nguyen Alexander Hieu | Chief Legal Officer |
Nov 04 '24 |
Sale |
1.29 |
149 |
192 |
24,723 |
| Nguyen Alexander Hieu | Chief Legal Officer |
Aug 02 '24 |
Sale |
1.53 |
154 |
236 |
24,872 |
| Ghosh Anirvan | Chief Executive Officer |
Aug 02 '24 |
Sale |
1.53 |
604 |
924 |
76,325 |
| Sullivan Lynne Marie | CFO & Head of Corp. Dev. |
Aug 02 '24 |
Sale |
1.53 |
139 |
213 |
56,061 |
| Nguyen Alexander Hieu | Chief Legal Officer |
Jun 25 '24 |
Sale |
1.40 |
78 |
109 |
25,026 |
| Ghosh Anirvan | Chief Executive Officer |
Jun 25 '24 |
Sale |
1.40 |
1,214 |
1,700 |
76,929 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):